Professor Soria talks to ecancertv about the upcoming Targeted Anticancer Therapies Congress (TAT 2015) and what sets it apart from other conferences. Particularly, he highlights the unique interactions which are facilitated between academia and industry, as well as young oncologists and those with more experience. With an emphasis on discussing new targets and agents in phase 1 or ready to go into phase 1, TAT draws participants from 40 different countries and is, Soria says "the home of phase 1".